par Renard, Marc 
;Jacobs, Paul ;Dechamps, Philippe
Référence Chest, 84, 4, page (408-413)
Publication Publié, 1983
;Jacobs, Paul ;Dechamps, Philippe Référence Chest, 84, 4, page (408-413)
Publication Publié, 1983
Article révisé par les pairs
| Résumé : | Sulmazol (AR-L 115 BS) is a new positively inotropic drug with arterial and venous vasodilating properties. We studied the effects of sulmazol (three-day infusion) on clinical tolerance, hemodynamics, and blood gas levels in ten patients with severe chronic heart failure. The hemodynamic monitoring included a Swan-Ganz catheter in the pulmonary artery and a radial catheter. Blood gas levels were determined on samples of arterial and mixed venous blood. After 24 hours of infusion, there was a significant increase in cardiac index (2 to 2.5 L/min/sq m; p<0.005) and a signification decrease in pulmonary-wedge pressure (28 to 19 mm Hg; p<0.001) and in right atrial pressure (7 to 4 mm Hg; p<0.001) without significant changes in heart rate and systolic blood pressure. These benefical effects lasted during the three days of infusion. Oxygen delivery was significantly increased (350 to 443 ml/min/sq m; p<0.005) without significant change in arterial oxygen tension. The side effects included nausea, vomiting, anorexia, and mild thrombocytopenia. We conclude that sulmazol is a potent drug which may improve severely deteriorated left and right ventricular function in patients with chronic refractory heart failure without affecting the heart rate and the systolic blood pressure. |
